Alzheimer’s Analysis UK stated it was “a bittersweet second”.
“The approval of lecanemab is a milestone second however the determination by NICE to not approve it for the NHS is deeply disappointing,” stated head of coverage, David Thomas.
Dr Samantha Roberts, chief govt of NICE, stated the physique had rigorously evaluated the out there proof, together with the profit for carers, however might solely advocate remedies that “supply good worth to the taxpayer”.
“Lecanemab offers on common 4 to 6 months’ slowing within the price of development from delicate to reasonable Alzheimer’s illness, however that is simply not sufficient profit to justify the extra value to the NHS,” stated Helen Knight, director of medicines analysis at NICE.
A last determination by NICE will come in the direction of the tip of the yr following a public session.
About 70,000 adults in England would have been eligible for therapy with lecanemab.
Wales and Northern Eire typically comply with medical steerage in England.
The physique which assesses newly licensed medicines in Scotland has not but decided on the worth of the drug.
NHS England stated a devoted group was taking a look at 27 different Alzheimer’s medication at the moment in superior trials that might be authorized within the coming years.
